KnowBe4 Delivers AI-Driven Email Security to Small and Medium Businesses to Tackle Outbound Email Risk
15.7.2025 14:00:00 CEST | Business Wire | Press Release
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today announced the release of KnowBe4 Prevent across all market segments – an AI-driven email security product designed to enable organizations to manage the problem of outbound email risk. Following the release of Prevent Enterprise, Prevent is now available to suit the needs of small to medium-sized businesses.
In 2025, human error remains the leading cause of data breaches (according to Verizon, 60% of incidents involve the ‘human element’). The overwhelming volume of digital communications creates more opportunities for employees to expose sensitive information to the wrong recipients, attaching incorrect files, or inadvertently including confidential data. These breaches incur severe penalties, financial losses, and reputational damage, underscoring the critical need for prevention. However, traditional Data Loss Prevention (DLP) offerings rely solely on inflexible static rules and lack real visibility into what is being sent, to whom, and when.
To address this challenge, KnowBe4 introduces Prevent, an AI-native outbound email security product that alerts your employees in real time when they are about to send emails and attachments to the wrong person. Prevent proactively detects and stops the full spectrum of outbound email security threats, including:
- Misdirected emails to incorrect recipients, including those as a result of autocomplete
- Unauthorized sharing of sensitive information
- Replies to suspicious emails and newly registered domains
- Data exfiltration attempts by malicious insiders or compromised accounts
- Misattached files, including hidden data within attachments (Prevent Enterprise)
- Internal unauthorized disclosure and breach of information barriers (Prevent Enterprise)
Combined with detailed reporting and analytics, security teams are able to get a complete view of outbound security risk across the organization, behavioral analytics of users’ interactions with Prevent’s prompts and quantification of the prevented incidents to demonstrate efficacy and return on investment (ROI).
“Outbound email risk continues to be one of the most persistent and costly challenges an organization can face – one that requires smarter, more adaptive approaches to effectively address them,” said Greg Kras, chief product officer at KnowBe4. “KnowBe4 has a proven track record of effectively addressing Human Risk Management, so we are proud to expand that coverage to include outbound email risk. Prevent is the most intelligent and proactive outbound email security product among today's email data loss prevention methods. Unlike traditional products, it uses advanced machine learning and contextual understanding of user behavior to identify risky actions in real time and prevent a data breach before it occurs. This allows organizations to stop incidents at the source, empower employees to make safer decisions, and enable security teams to manage and reduce risk at scale.”
For more information on how KnowBe4 Prevent can help organizations mitigate outbound data loss over email, visit www.knowbe4.com/products/prevent. See how it helped KnowBe4 customer Publix Employee Federal Credit Union here.
About KnowBe4
KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset. More at https://knowbe4.com.
Follow KnowBe4 on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250715426192/en/
Contacts
Media Contact:
Amanda Tarantino
Sr. Manager of Public Relations
amandat@knowbe4.com
727-748-4221
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom